Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles

References

• Temel JS, Gainor JF, Sullivan RJ, et al. Keeping expectations in check with immune checkpoint inhibitors. J Clin Oncol. 2018;36:1654–1657.
   PubMedGoogle Scholar
• Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018;18:139–147.
   PubMed Web of Science ®Google Scholar
• Lafolla MAJ, Selby H, Warner K, et al. Rational design and identification of immuno-oncology drug combinations. Eur J Cancer. 2018;95:38–51.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–489.
   PubMed Web of Science ®Google Scholar
• Chabanon RM, Pedrero M, Lefebvre C, et al. Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res. 2016;22:4309–4321.
   PubMed Web of Science ®Google Scholar
• Roselli M, Cereda V, Di Bari MG, et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology. 2013;2:e27025.
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Punt CJA, Hato SV, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011;121:3100–3108.
   PubMed Web of Science ®Google Scholar
• Jurj A, Braicu C, Pop L-A, et al. The new era of nanotechnology, an alternative to change cancer treatment [Internet]. Drug Des Develop Ther. 2017;11:2871–2890.
   PubMed Web of Science ®Google Scholar
• Fanciullino R, Ciccolini J, Milano G. Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. Crit Rev Oncol Hematol. 2013;88:504–513.
   PubMed Web of Science ®Google Scholar
• Rodallec A, Fanciullino R, Lacarelle B, et al. Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles. Expert Rev Clin Pharmacol. 2018;11:599–610.
   PubMed Web of Science ®Google Scholar
• Tseng S-H, Chou M-Y, Chu I-M. Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy. Int J Nanomed. 2015;10:3663–3685.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang P, Li F, et al. Metal-based nanoenhancers for future radiotherapy: radiosensitizing and synergistic effects on tumor cells. Theranostics. 2018;8:1824–1849.
   PubMed Web of Science ®Google Scholar
• Shah A, Dobrovolskaia MA. Immunological effects of iron oxide nanoparticles and iron-based complex drug formulations: therapeutic benefits, toxicity, mechanistic insights, and translational considerations. Nanomedicine. 2018;14:977–990.
   PubMed Web of Science ®Google Scholar
• Kurtin S. Myeloid toxicity of cancer treatment. J Adv Pract Oncol. 2012;3:209–224.
   PubMedGoogle Scholar
• Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. OncoTargets Ther. 2018;11:955–965.
   PubMed Web of Science ®Google Scholar
• Putzu C, Cortinovis DL, Colonese F, et al. Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab. Cancer Immunol Immunother. 2018;67:1349–1353.
   PubMed Web of Science ®Google Scholar
• Liu L-T, Chen Q-Y, Tang L-Q, et al. The prognostic value of treatment-related lymphopenia in nasopharyngeal carcinoma patients. Cancer Res Treat. 2018;50:19–29.
   PubMedGoogle Scholar
• Wild AT, Ye X, Ellsworth SG, et al. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol. 2015;38:259–265.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Diehl A, Johnson BA, et al. Relationship between lymphopenia and objective response rate with programmed death-1 (PD-1) inhibitor therapy: a single-center retrospective analysis. Jco. 2017;35:e14512–e14512.
   Web of Science ®Google Scholar
• Sun R, Champiat S, Dercle L, et al. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). Eur J Cancer. 2017;84:202–211.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59–73.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317–1324.
   PubMed Web of Science ®Google Scholar
• Rafiyath SM, Rasul M, Lee B, et al. Comparison of safety and toxicity of liposomal doxorubicin vs conventional anthracyclines: a meta-analysis. Exp Hematol Oncol. 2012;1:10.
   PubMedGoogle Scholar
• O’Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult philadelphia chromosome–negative acute lymphoblastic leukemia. J Clin Oncol. 2013;31:676–683.
   PubMed Web of Science ®Google Scholar
• Fanciullino R, Mollard S, Giacometti S, et al. In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicity. Pharm Res. 2013;30:1281–1290.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil–based paclitaxel in women with breast cancer. J Thoracic Oncol. 2005;23:7794–7803.
   Google Scholar
• Ait-Oudhia S, Straubinger RM, Mager DE. Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm Res. 2012;29:2833–2844.
   PubMed Web of Science ®Google Scholar
• Adiwijaya BS, Kim J, Lang I, et al. Population pharmacokinetics of liposomal irinotecan in patients with cancer. Clin Pharmacol Ther. 2017;102:997–1005.
   PubMed Web of Science ®Google Scholar
• Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29:1437–1444. *: clinical evidences suggesting that avoiding chemotherapy-related hematological toxicities could improve efficacy of immunotherapy.
   PubMed Web of Science ®Google Scholar
• Yi M, Yu S, Qin S, et al. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol. 2018;11:47.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74.
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30:61–69.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Long GV, Scolyer RA, et al. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81.
   PubMed Web of Science ®Google Scholar
• Green DR, Ferguson T, Zitvogel L, et al. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009;9:353–363.
   PubMed Web of Science ®Google Scholar
• Fanciullino R, Giacometti S, Mercier C, et al. In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation. Br J Cancer. 2007;97:919–926.
   PubMed Web of Science ®Google Scholar
• Bornmann C, Graeser R, Esser N, et al. A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging. Cancer Chemother Pharmacol. 2008;61:395–405.
   PubMed Web of Science ®Google Scholar
• Kim M, Daunorubicin WS. Cytarabine liposome in newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes. Ann Pharmacother. 2018;52:792–800.
   PubMed Web of Science ®Google Scholar
• Jeanbart L, Ballester M, de Titta A, et al. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res. 2014;2:436–447.
   PubMed Web of Science ®Google Scholar
• Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother. 2013;62:203–216.
   PubMed Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3:436–443.
   PubMed Web of Science ®Google Scholar
• Katsuya Y, Horinouchi H, Asao T, et al. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer. 2016;99:4–10.
   PubMed Web of Science ®Google Scholar
• Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med. 2005;201:1591–1602.
   PubMed Web of Science ®Google Scholar
• Kaneno R, Shurin GV, Tourkova IL, et al. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med. 2009;7:58.
   PubMed Web of Science ®Google Scholar
• Shurin GV, Tourkova IL, Kaneno R, et al. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol. 2009;183:137–144.
   PubMed Web of Science ®Google Scholar
• McKenzie JA, Mbofung RM, Malu S, et al. The effect of topoisomerase i inhibitors on the efficacy of T-cell-based cancer immunotherapy. J Natl Cancer Inst. 2018;110:777–786.
   PubMedGoogle Scholar
• Rodallec A, Benzekry S, Lacarelle B, et al. Pharmacokinetics variability: why nanoparticles are not just magic-bullets in oncology. Crit Rev Oncol Hematol. 2018;129:1–12.
   PubMed Web of Science ®Google Scholar
• Ilinskaya AN, Dobrovolskaia MA. Understanding the immunogenicity and antigenicity of nanomaterials: past, present and future. Toxicol Appl Pharmacol. 2016;299:70–77.
   PubMed Web of Science ®Google Scholar
• Sauerborn M, Brinks V, Jiskoot W, et al. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci. 2010;31:53–59.
   PubMed Web of Science ®Google Scholar
• Zolnik BS, González-Fernández A, Sadrieh N, et al. Nanoparticles and the immune system. Endocrinology. 2010;151:458–465.
   PubMed Web of Science ®Google Scholar
• Banerji B, Kenny JJ, Scher I, et al. Antibodies against liposomes in normal and immune-defective mice. J Immunol. 1982;128:1603–1607.
   PubMed Web of Science ®Google Scholar
• Neun BW, Barenholz Y, Szebeni J, et al. Understanding the role of anti-PEG antibodies in the complement activation by doxil in vitro. Molecules. 2018;23:1700.
   Web of Science ®Google Scholar
• Shimizu T, Ishida T, Kiwada H. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology. 2013;218:725–732.
   PubMed Web of Science ®Google Scholar
• Shahbazi M-A, Shrestha N, Mäkilä E, et al. A prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors. Nano Res. 2015;8:1505–1521.
   Web of Science ®Google Scholar
• Ahmed M, Pan DW, Davis ME. Lack of in vivo antibody dependent cellular cytotoxicity with antibody containing gold nanoparticles. Bioconjug Chem. 2015;26:812–816.
   PubMed Web of Science ®Google Scholar
• Zhu S, Niu M, O’Mary H, et al. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol Pharm. 2013;10:3525–3530.
   PubMedGoogle Scholar
• Perica K, De León Medero A, Durai M, et al. Nanoscale artificial antigen presenting cells for T cell immunotherapy. Nanomedicine. 2014;10:119–129.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine. 2002;20(Suppl 4):A46–51.
   PubMedGoogle Scholar
• Demaria S, Volm MD, Shapiro RL, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. 2001;7:3025–3030.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Vétizou M, Daillère R, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44:1255–1269.
   PubMed Web of Science ®Google Scholar
• Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271:58–65.
   PubMed Web of Science ®Google Scholar
• Conde J, Bao C, Tan Y, et al. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells. Adv Funct Mater. 2015;25:4183–4194.
   PubMed Web of Science ®Google Scholar
• Jain NK, Tare MS, Mishra V, et al. The development, characterization and in vivo anti-ovarian cancer activity of poly(propylene imine) (PPI)-antibody conjugates containing encapsulated paclitaxel. Nanomedicine. 2015;11:207–218.
   PubMed Web of Science ®Google Scholar
• Duan X, Chan C, Guo N, et al. Photodynamic therapy mediated by nontoxic core-shell nanoparticles synergizes with immune checkpoint blockade to elicit antitumor immunity and antimetastatic effect on breast cancer. J Am Chem Soc. 2016;138:16686–16695.
   PubMed Web of Science ®Google Scholar
• Zhang F, Stephan SB, Ene CI, et al. Nanoparticles that reshape the tumor Milieu create a therapeutic window for effective T-cell therapy in solid malignancies. Cancer Res. 2018;78:3718–3730.
   PubMed Web of Science ®Google Scholar
• Tang L, Zheng Y, Melo MB, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol [Internet]. 2018;36:707–716.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Dash SK, Mandal D, et al. Metal based nanoparticles as cancer antigen delivery vehicles for macrophage based antitumor vaccine. Vaccine. 2016;34:957–967.
   PubMed Web of Science ®Google Scholar
• Amini MA, Abbasi AZ, Cai P, et al. Combining tumor microenvironment modulating nanoparticles with doxorubicin to enhance chemotherapeutic efficacy and boost antitumor immunity. J Natl Cancer Inst. 2018. Epub ahead of print. DOI:10.1093/jnci/djy131.
   PubMedGoogle Scholar
• Meng H, Leong W, Leong KW, et al. Walking the line: the fate of nanomaterials at biological barriers. Biomaterials. 2018;174:41–53.
   PubMed Web of Science ®Google Scholar
• Kareva I. A combination of immune checkpoint inhibition with metronomic chemotherapy as a way of targeting therapy-resistant cancer cells. Int J Mol Sci. 2017;18:E2134.
   PubMed Web of Science ®Google Scholar
• Warheit DB. Hazard and risk assessment strategies for nanoparticle exposures: how far have we come in the past 10 years? F1000Res. 2018;7:376.
   PubMedGoogle Scholar